- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00881777
Feasibility Study of Radiofrequency Heating of Cardiac Infarction Scar to Treat Heart Failure (RECOVER)
July 12, 2011 updated by: CoRepair, Inc.
Radiofrequency Energy Use in Cardiomyopathy and Ventricular Enlargement (RECOVER)
The purpose of this study is to examine the safety and potential effectiveness of a new surgical procedure for treating heart failure.
The experimental treatment is performed during standard coronary artery bypass graft (CABG) surgery, and applies radiofrequency energy to heat a portion of the damaged heart muscle.
The tissue heating reduces the enlarged heart of patients suffering from ischemic heart failure, and may result in the heart pumping blood more efficiently, thereby improving the functional status of the patient.
Study Overview
Status
Terminated
Conditions
Detailed Description
Heart failure is an important health-care problem, resulting in significant numbers of patients, hospitalizations, and economic costs.
The etiology of heart failure is coronary artery disease in approximately two-thirds of cases, and the majority of these patients have experienced prior myocardial infarction.
As a consequence of the myocardial infarction, the ventricle undergoes changes in volume and shape, a process referred to as "ventricular remodeling".
As the left ventricle enlarges, global systolic function worsens, resulting in heart failure.
There are a number of treatment options available to minimize symptoms and somewhat slow disease progression.
Unfortunately, even with best conventional drug and device therapies, heart failure patients continue to have high morbidity and mortality rates.
The experimental therapy investigated in this study uses a surgical device which employs radiofrequency energy to heat epicardial tissue.
The application of heat to a myocardial infarction scar causes it to shrink in size, and correspondingly reduces ventricular volume.
The volume reduction may "reverse remodel" the enlarged and dysfunctioning left ventricle to a more normal size and shape.
The intent of this clinical study is to evaluate whether radiofrequency heating of the myocardial infarct scar is safe, and determine if the resulting ventricular volume reduction translates into improved clinical and functional outcomes in patients suffering from ischemic heart failure.
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 to 80 years, inclusive
- Symptomatic heart failure (defined as persistent NYHA class II or III during the 3 months prior to enrollment)
- On evidence-based medical therapy for heart failure during the 1 month prior to enrollment
- Referred for elective coronary artery bypass grafting
- Dyskinetic transmural myocardial infarct located in the apical portion of the anterior, lateral, and/or inferior left ventricular wall as determined by transthoracic echocardiography ("transmural" means end-diastolic wall thickness of 4 - 6 mm, inclusive)
- Left ventricular ejection fraction 20 - 45%, inclusive as determined by transthoracic echocardiography
- Left ventricular end-systolic volume index ≥ 60 ml/m2 as determined by transthoracic echocardiography
- 6-minute walk distance over 150 m
- Peak VO2 (ml/kg/min): 10.0 - 20.0 for males and 9.0 - 18.0 for females
Exclusion Criteria:
- Myocardial infarction ≤ 3 months prior to enrollment
- Evidence of calcification within the scar intended to be treated by any imaging modality
- Presence of a coronary stent within the scar intended to be treated
- Evidence of left ventricular thrombus
- Emergent cardiac surgery
- Percutaneous coronary intervention (PCI) ≤ 1 month prior to enrollment or planned following enrollment
- Only for patients undergoing MR (rather than CT) imaging: Contraindications for MRI (current or anticipated during the 6 months following enrollment), such as pacemaker, Automatic Implantable Cardioverter-Defibrillator (AICD), Cardiac Resynchronization Therapy (CRT) device, central nervous system aneurysm clips, Cochlear implant, or metal shrapnel
- Only for patients undergoing MR (rather than CT) imaging: Acute or chronic severe renal insufficiency (i.e. a glomerular filtration rate < 30 ml/min/1.73m2) or acute renal insufficiency of any severity due to hepato-renal syndrome
- Only for patients undergoing MR (rather than CT) imaging: Known allergy or reaction to Gadolinium
- Atrial fibrillation
- Prior cardiac surgery (including coronary artery bypass grafting, valve replacement or repair, aortic root replacement) or anticipated during the 6 months following enrollment
- Major non-cardiac surgery (e.g. knee or hip replacement, laparotomy, carotid endarterectomy, etc.) ≤ 3 months prior to enrollment or planned during the 6 months following enrollment
- Prior heart, kidney, liver, or lung transplantation
- Valvular heart disease requiring replacement or repair (e.g. mitral valve regurgitation ≥ 3+)
- Cardiogenic shock ≤ 72 hours prior to the CABG surgery (defined as need for Intra-Aortic Balloon Pump or requiring intravenous inotropic support)
- Currently needing (or anticipated need for) Left Ventricular Assist Device or other cardiac replacement device
- On active heart transplant list or anticipated need for transplant during the 6 months following enrollment
- Stoke or transient ischemic attack ≤ 3 months prior to enrollment
- Chronic dialysis
- Major infection or sepsis ≤ 72 hours of enrollment (defined as requiring IV antibiotics for > 3 days)
- Endocarditis, myocarditis, or pericarditis
- Co-morbid condition that, in the investigator's opinion, results in the patient's life expectancy being < 180 days
- Evidence of significant blood chemistry abnormalities, including creatinine > 2.5 mg/dl, BUN ≥ 100 mg/dl, liver function tests > 3 times upper limit of normal, Hgb < 10 gm/dl, HCT < 25%, platelet count < 100,000/mm3, or white blood cell count < 3,000/mm3 or > 20,000/mm3
- Females of child-bearing potential without a documented negative pregnancy test within the 14 days prior to enrollment (and prior to the MRI or CT) or who are unwilling to use effective contraception for the duration of this study
- Participation in another investigational device or drug trial
- Unable or unwilling to give Informed Consent
- Unwilling or unlikely to complete the required follow-up
- Any other medical condition that, in the judgment of the investigator, would cause this study to be detrimental to the patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RF Heating + CABG
Radiofrequency heating of the myocardial infarct scar plus Coronary Artery Bypass Grafting (CABG) surgery
|
Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease.
Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
|
Active Comparator: CABG Alone
Coronary Artery Bypass Grafting (CABG) surgery only, without radiofrequency heating of the myocardial infarct scar
|
A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease.
Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Left Ventricular End Diastolic and Systolic Volume Indexes as measured by Cardiac MRI/CT
Time Frame: 6 Months
|
6 Months
|
Occurrence of any of the following: cardiac hemorrhage/rupture, cardiac tamponade, stroke/transient ischemic attack/renal failure, myocardial infarction, sepsis/cardiac-related infection, re-hospitalization for cardiac cause, or all-cause mortality
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Left Ventricular End Diastolic and Systolic Dimensions, Volumes, and Volume Indexes, and Left Ventricular Ejection Fraction as measured by Cardiac MRI/CT
Time Frame: Peri-operative, 6 and 12 months
|
Peri-operative, 6 and 12 months
|
Change in New York Heart Association Functional Classification and Canadian Cardiovascular Society Angina Grading Scale
Time Frame: 1, 3, 6, and 12 months
|
1, 3, 6, and 12 months
|
Change in Cardiopulmonary Exercise Stress Test (Peak VO2 and VE/VCO2 slope)
Time Frame: 6 and 12 months
|
6 and 12 months
|
Change in 6-Minute Walk distance
Time Frame: 1, 3, 6, and 12 months
|
1, 3, 6, and 12 months
|
Change in Quality of Life Questionnaire score (Minnesota Living With Heart Failure and EuroQol EQ-5D)
Time Frame: 1, 3, 6, and 12 months
|
1, 3, 6, and 12 months
|
Occurrence of individual primary safety endpoints, heart failure deaths, heart failure hospitalizations, all-cause hospitalizations, days alive out of the hospital, and neurological assessments (NIH Stroke Scale and Mini-Mental Status Exam)
Time Frame: 6 and 12 months
|
6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ratcliffe MB, Wallace AW, Teerlink JR, Hong J, Salahieh A, Sung SH, Keung EC, Lee RJ. Radio frequency heating of chronic ovine infarct leads to sustained infarct area and ventricular volume reduction. J Thorac Cardiovasc Surg. 2000 Jun;119(6):1194-204. doi: 10.1067/mtc.2000.105826.
- Victal OA, Teerlink JR, Gaxiola E, Wallace AW, Najar S, Camacho DH, Gutierrez A, Herrera G, Zuniga G, Mercado-Rios F, Ratcliffe MB. Left ventricular volume reduction by radiofrequency heating of chronic myocardial infarction in patients with congestive heart failure. Circulation. 2002 Mar 19;105(11):1317-22. doi: 10.1161/hc1102.105566.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
April 13, 2009
First Submitted That Met QC Criteria
April 14, 2009
First Posted (Estimate)
April 15, 2009
Study Record Updates
Last Update Posted (Estimate)
July 14, 2011
Last Update Submitted That Met QC Criteria
July 12, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008-01 Rev. C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
Clinical Trials on Radiofrequency heating of the myocardial infarct scar
-
University of PennsylvaniaRecruitingCardiovascular DiseasesUnited States
-
University of Maryland, BaltimoreNational Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Arrhythmia | Ventricular FibrillationUnited States
-
S.M. Misericordia HospitalUnknownAcute Myocardial Infarction, Coronary Stent Thrombosis, Antithrombotic TherapyItaly
-
Lithuanian Sports UniversityCompletedMultiple SclerosisLithuania
-
Ziekenhuis Oost-LimburgBelgium Health Care Knowledge Centre; Klinische Epidemiologie en Medical Technology...RecruitingKnee Osteoarthritis | Chronic Knee Pain | Persistent Postsurgical PainBelgium, Netherlands
-
Diskapi Teaching and Research HospitalCompletedTrigeminal NeuralgiaTurkey
-
University Hospital, Clermont-FerrandRecruitingAbdominal Pain | Cesarean Section | Morbidity | PostpartumFrance
-
Diskapi Teaching and Research HospitalCompletedHeadache Disorders | Trigeminal NeuralgiaTurkey
-
Beijing Haidian HospitalBeijing Fangshan District Liangxiang HospitalUnknownDiagnoses Disease | Acute Myocardial Infarction | Cardiac DiseaseChina